Trafalgar International (GCAN) Cash & Equivalents Growth (3y) (2020 - 2026)
Trafalgar International (GCAN) Cash & Equivalents Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | 21.81% |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 11.05% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -4.92% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 7.80% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 19.10% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 12.11% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 27.55% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 13.03% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | 32.82% |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.12% |
| Dec 31, 2025 | -85.55% |
| Jun 30, 2025 | -55.89% |
| Dec 31, 2024 | -46.64% |
| Sep 30, 2024 | -48.51% |
| Jun 30, 2024 | -46.65% |
| Mar 31, 2024 | -25.81% |
| Dec 31, 2023 | 13.89% |
| Jun 30, 2023 | 1.75% |
| Dec 31, 2022 | 122.06% |
| Jun 30, 2022 | 56.60% |
| Dec 31, 2021 | 84.73% |
| Sep 30, 2021 | 73.26% |
| Mar 31, 2021 | 58.70% |
| Dec 31, 2020 | 384.52% |
| Sep 30, 2020 | 464.51% |
| Jun 30, 2020 | 572.90% |
| Mar 31, 2020 | 632.95% |